Brief: Rani Therapeutics Announces Successful Oral Delivery Of Monoclonal Antibody Via High-Capacity Pill In Preclinical Study
19/10/2023 21:58
Oct 19 (Reuters) - Rani Therapeutics Holdings Inc
RANI.O :
* RANI THERAPEUTICS ANNOUNCES SUCCESSFUL ORAL DELIVERY OF
MONOCLONAL ANTIBODY VIA HIGH-CAPACITY PILL IN PRECLINICAL STUDY
* RANI THERAPEUTICS HOLDINGS INC - RANIPILL®HC ACHIEVED 4/4
SUCCESSFUL DRUG DELIVERY OF ORALLY ADMINISTERED HUMIRA®
(ADALIMUMAB)
* RANI THERAPEUTICS HOLDINGS INC - RANIPILL® HC HAS ACHIEVED
A
CUMULATIVE >90% SUCCESS RATE ACROSS MULTIPLE PRECLINICAL STUDIES
Source text for Eikon: ID:nGNX5cN4PF
Further company coverage: RANI.O
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition